Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised EQT AB (publ) in connection with the entry into of a EUR 1,000,000,000 revolving credit facility agreement.
Mandate

Vinge has advised EQT AB (publ) in connection with the entry into of a EUR 1,000,000,000 revolving credit facility agreement.

December 22, 2020 Banking and Finance

The financing is intended to be used for EQT’s general corporate purposes, including supporting its growth initiatives and long-term strategy.

The agreement contains a possibility to connect pricing to EQT’s compliance with certain ESG-targets. The financing was arranged by Nordea and SEB and the syndicate of banks contained 13 global financial institutions.

The Vinge team primarily consisted of Louise Brorsson Salomon, Ludvig Wettergren och Rebecka Målquist.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026